Patents by Inventor Xinghua Pang

Xinghua Pang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN BINDING FRAGMENTS, PHARMACEUTICAL COMPOSITIONS AND USES
    Publication number: 20230064544
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
    Type: Application
    Filed: March 15, 2022
    Publication date: March 2, 2023
    Applicant: AKESO BIOPHARMA, INC.
    Inventors: Baiyong LI, Yu XIA, Zhongmin WANG, Peng ZHANG, Xinghua PANG
  • Anti-CTLA4 antibodies
    Patent number: 11479608
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology. The present invention relates to an anti-CTLA4 antibody, pharmaceutical composition and use thereof. The anti-CTLA4 antibody of the present invention can specifically bind CTLA4, and can very effectively block the binding of CLTA4 to B7.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: October 25, 2022
    Assignee: Akeso Biopharma, Inc.
    Inventors: Baiyong Li, Yu Xia, Peng Zhang, Xinghua Pang, Zhongmin Wang
  • Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses
    Patent number: 11291720
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: April 5, 2022
    Assignee: AKESO BIOPHARMA, INC.
    Inventors: Baiyong Li, Yu Xia, Zhongmin Wang, Peng Zhang, Xinghua Pang
  • ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN BINDING FRAGMENTS, PHARMACEUTICAL COMPOSITIONS AND USES
    Publication number: 20200206346
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
    Type: Application
    Filed: September 5, 2019
    Publication date: July 2, 2020
    Inventors: Baiyong LI, Yu XIA, Zhongmin WANG, Peng ZHANG, Xinghua PANG
  • Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses
    Patent number: 10449251
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CTLA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: October 22, 2019
    Assignee: AKESO BIOPHARMA, INC.
    Inventors: Baiyong Li, Yu Xia, Zhongmin Wang, Peng Zhang, Xinghua Pang
  • ANTI-CTLA4 ANTIBODIES
    Publication number: 20190177414
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology. The present invention relates to an anti-CTLA4 antibody, pharmaceutical composition and use thereof. The anti-CTLA4 antibody of the present invention can specifically bind CTLA4, and can very effectively block the binding of CLTA4 to B7.
    Type: Application
    Filed: August 21, 2017
    Publication date: June 13, 2019
    Applicant: Akeso Biopharma, Inc.
    Inventors: Baiyong LI, Yu XIA, Peng ZHANG, Xinghua PANG, Zhongmin WANG
  • AN ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN BINDING FRAGMENTS, PHARMACEUTICAL COMPOSITIONS AND USES
    Publication number: 20170216433
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
    Type: Application
    Filed: July 31, 2015
    Publication date: August 3, 2017
    Inventors: Baiyong Li, Yu Xia, Zhongmin Wang, Peng Zhang, Xinghua Pang